000 -LEADER |
fixed length control field |
03410nam a22004815i 4500 |
001 - CONTROL NUMBER |
control field |
978-1-59745-169-7 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
DE-He213 |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20161121230840.0 |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
fixed length control field |
cr nn 008mamaa |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
100301s2008 xxu| s |||| 0|eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
9781597451697 |
-- |
978-1-59745-169-7 |
024 7# - OTHER STANDARD IDENTIFIER |
Standard number or code |
10.1007/978-1-59745-169-7 |
Source of number or code |
doi |
050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
Classification number |
RC261-271 |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MJCL |
Source |
bicssc |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MED062000 |
Source |
bisacsh |
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
Classification number |
614.5999 |
Edition number |
23 |
245 10 - TITLE STATEMENT |
Title |
Cancer Proteomics |
Medium |
[electronic resource] : |
Remainder of title |
From Bench to Bedside / |
Statement of responsibility, etc. |
edited by Sayed S. Daoud. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
Place of production, publication, distribution, manufacture |
Totowa, NJ : |
Name of producer, publisher, distributor, manufacturer |
Humana Press, |
Date of production, publication, distribution, manufacture, or copyright notice |
2008. |
300 ## - PHYSICAL DESCRIPTION |
Extent |
XII, 264 p. 5 illus. in color. |
Other physical details |
online resource. |
336 ## - CONTENT TYPE |
Content type term |
text |
Content type code |
txt |
Source |
rdacontent |
337 ## - MEDIA TYPE |
Media type term |
computer |
Media type code |
c |
Source |
rdamedia |
338 ## - CARRIER TYPE |
Carrier type term |
online resource |
Carrier type code |
cr |
Source |
rdacarrier |
347 ## - DIGITAL FILE CHARACTERISTICS |
File type |
text file |
Encoding format |
PDF |
Source |
rda |
490 1# - SERIES STATEMENT |
Series statement |
Cancer Drug Discovery and Development |
505 0# - FORMATTED CONTENTS NOTE |
Formatted contents note |
Proteomics Technologies -- Current and Emerging Mass Spectrometry Instrumentation and Methods for Proteomic Analyses -- Cell Signaling Proteomics -- Integration of Genomics and Proteomics in Dissecting p53 Signaling -- Proteomic Profiling of Tyrosine Kinases as Pharmacological Endpoints for Targeted Cancer Therapy -- Tumor Proteomics -- Oncoproteomics for Personalized Management of Cancer -- Application of Serum and Tissue Proteomics to Understand and Detect Solid Tumors -- Insight on Renal Cell Carcinoma Proteome -- Proteomics in Lung Cancer -- Proteomic Strategies of Therapeutic Individualization and Target Discovery in Acute Myeloid Leukemia -- New Tumor Biomarkers -- Bioinformatics and Regulatory Aspects of Proteomics -- Annotating the Human Proteome -- Regulatory Issues in the Co-Development of Oncology Drugs and Proteomic Tests: An Overview. |
520 ## - SUMMARY, ETC. |
Summary, etc. |
Over the past 20 years or so, there have been tremendous advances in our understanding of how normal cells transform to cancer and the importance of signaling pathways in cancer initiation and progression. Therefore, proteomics technologies must be improved for more global analysis of protein content of cells, tissues and body fluids as well as the posttranslational modifications to allow for proper detections and validation. In Cancer Proteomics, the authors collectively provide the current status of proteomics in cancer therapy and offers the existing technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise of predicting response to specific drugs in cancer therapy. Insightful to the reader with broad perspectives on topics related to the use of proteomic strategies in cancer therapy, Cancer Proteomics offers anticipated challenges that may arise from its application in daily practice. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Medicine. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Cancer research. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Oncology. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Proteomics. |
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Biomedicine. |
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Cancer Research. |
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Proteomics. |
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Oncology. |
700 1# - ADDED ENTRY--PERSONAL NAME |
Personal name |
Daoud, Sayed S. |
Relator term |
editor. |
710 2# - ADDED ENTRY--CORPORATE NAME |
Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
773 0# - HOST ITEM ENTRY |
Title |
Springer eBooks |
776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
Relationship information |
Printed edition: |
International Standard Book Number |
9781588298584 |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
Uniform title |
Cancer Drug Discovery and Development |
856 40 - ELECTRONIC LOCATION AND ACCESS |
Uniform Resource Identifier |
http://dx.doi.org/10.1007/978-1-59745-169-7 |
912 ## - |
-- |
ZDB-2-SME |